Johnson Anne Nagengast 4
4 · ATAI Life Sciences N.V. · Filed Oct 4, 2024
Insider Transaction Report
Form 4
Johnson Anne Nagengast
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option
2024-10-04−326,416→ 0 totalExercise: $5.68Exp: 2025-08-20→ Common Shares (326,416 underlying) - Award
Stock Option
2024-10-04+326,416→ 326,416 totalExercise: $5.68Exp: 2030-08-20→ Common Shares (326,416 underlying) - Award
Stock Option
2024-10-04+115,152→ 115,152 totalExercise: $11.71Exp: 2030-08-20→ Common Shares (115,152 underlying) - Disposition to Issuer
Stock Option
2024-10-04−115,152→ 0 totalExercise: $11.71Exp: 2025-08-20→ Common Shares (115,152 underlying)
Footnotes (3)
- [F1]No new stock options have been awarded. The transactions reported herein reflect the extension of the expiration date of certain pre-IPO stock options to align them with options granted under the Issuer's 2021 Incentive Award Plan, which is consistent with prevailing market practices.
- [F2]The stock option is fully vested and currently exercisable.
- [F3]The stock option vested as to 25% of the underlying shares on April 29, 2022, and the remaining underlying shares vest in 36 substantially equal monthly installments thereafter.